6533b7d0fe1ef96bd125a5d9
RESEARCH PRODUCT
Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes
Vesna Spasojevic-kalimanovskaSocrates PastromasAleksandra ZeljkovicAntonis S. ManolisDimitri P. MikhailidisJelena VekicDimitrios SakellariouZorana Jelic-ivanovicManfredi RizzoGiovam Battista RiniSpyridon Koulourissubject
Malehigh-density lipoproteinsmedicine.medical_specialtyType 2 diabetes030204 cardiovascular system & hematologysizeStatistics NonparametricRosiglitazone03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicinelow-density lipoproteinsHumansHypoglycemic AgentsProspective Studies030212 general & internal medicineGlycated Hemoglobindiabetesbusiness.industryFastingMiddle AgedPostprandial Periodmedicine.diseaseLipids3. Good healthLipoproteins LDLPostprandialEndocrinologyDiabetes Mellitus Type 2FemaleThiazolidinedioneslipids (amino acids peptides and proteins)HemoglobinsubclassesLipoproteins HDLCardiology and Cardiovascular MedicineRosiglitazonebusinessPioglitazoneDyslipidemiamedicine.drugLipoproteindescription
Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbA1c] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased (+1.4%, P = .034), with less small, dense LDL-IIIA (-25.1%, P = .018). Postprandially, larger HDL-2b reduced (-8.7%, P = .006) and smaller HDL-3b increased (+12.2%, P = .05), without any effects on HDL size. Rosiglitazone led to antiatherogenic changes in LDL size and subclasses, with proatherogenic changes in HDL subclasses, despite no effects on plasma lipids. Their clinical relevance remains to be established.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2010-05-12 |